IRIXNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends January 3
IRIDEX CORP
Financials through Q2 FY2026, quarter ended Jul 4, 2026Last filing: 10-Q on Aug 18, 2026
$0.77−0.04 (-5.48%)
Close on Oct 19, 2026
- Market cap
- $13.41M
- P/E (TTM)
- –
- Dividend yield
- –
IRIDEX CORP revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Retina | $27.90M | $29.46M | $30.28M | $28.70M | $28.45M | $27.70M | $27.83M | $28.03M | $29.44M | $29.01M | $29.45M | $30.01M | 54.1% | -1.9% |
| Cyclo G6 | $14.93M | $14.31M | $13.84M | $13.29M | $12.88M | $12.93M | $12.70M | $12.51M | $12.42M | $12.75M | $13.46M | $14.59M | 29.0% | +15.9% |
| Other | $8.74M | $8.81M | $8.55M | $8.66M | $8.41M | $8.18M | $8.15M | $7.90M | $7.83M | $8.17M | $8.96M | $10.01M | 17.0% | +3.9% |
| Service Contract Revenues | – | – | – | $2.39M | $2.99M | $2.93M | $1.40K | $2.26M | $1.66M | $1.36M | $1.53M | $1.47M | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $23.17M | $23.80M | $23.21M | $22.94M | $22.81M | $22.65M | $22.69M | $22.78M | $23.46M | $24.60M | $26.05M | $28.03M | 44.9% | +1.5% |
| Europe, Middle East and Africa | $14.67M | $14.87M | $14.39M | $13.20M | $11.97M | $10.99M | $11.82M | $11.47M | $12.86M | $13.04M | $13.52M | – | 28.4% | +22.5% |
| Asia/Pacific Rim | $11.37M | $11.63M | $12.95M | $12.30M | $12.94M | $12.87M | $11.95M | $12.22M | $11.65M | $10.54M | $10.23M | $8.74M | 22.0% | -12.2% |
| Americas, excluding the U.S. | $2.37M | $2.28M | $2.12M | $2.20M | $2.01M | $2.30M | $2.21M | $1.96M | $1.73M | $1.75M | $2.06M | – | 4.6% | +17.7% |
From the segment and revenue-disaggregation notes of Iridex's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.